Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma

NCT06422858 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Serplulimab
DRUG: Tegafur-gimeracil-oteracil potassium capsule(S1)
RADIATION: Radiotherapy
DRUG: Cisplatin

Sponsor

Zhejiang Cancer Hospital